Kenya has started giving the first doses of a groundbreaking HIV prevention drug called Lenacapavir in a Nairobi slum. The drug, taken just twice a year, has been shown to reduce the risk of HIV infection by more than 99.9 percent. Although many people call it a “vaccine,” it is actually a chemical prevention drug because it does not train the immune system.
The launch took place in Nairobi, where the first injections were administered in the Kawangware area. Health Minister Aden Duale described the moment as one of hope for thousands of families, especially young people who remain at high risk of infection.
Kenya is one of nine African countries chosen to introduce lenacapavir. The drug has already been rolled out in South Africa, Eswatini, and Zambia.
About 1.3 million people in Kenya are living with HIV, with the highest number of cases among those aged 15 to 24. Officials say the new drug will be provided for free. Kenya recently received 21,000 doses through an agreement with Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Health workers say the twice-a-year injection offers more privacy and convenience compared to frequent clinic visits. For many, it represents renewed strength in the country’s long fight against HIV.
SOURCE: TRT AFRICA
